Headquartered in Road No. 3, Hyderabad Fiscal year ends March NYSE: RDY drreddys.com
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company that develops, manufactures, and markets generic, biosimilar, and specialty pharmaceutical products globally. The company operates through three primary segments: Global Generics (encompassing branded and unbranded formulations across North America, India, Emerging Markets, and Europe), Pharmaceutical Services and Active Ingredients (PSAI, providing APIs and custom pharmaceutical services), and a Nicotine Replacement Therapy business integrated from Haleon. Approximately 52% of its business is in branded markets. The company is building growth platforms in peptides (including generic semaglutide for Type-2 diabetes), biosimilars (abatacept, rituximab), and consumer health through partnerships with companies like Nestlé. It has filed semaglutide applications in approximately 30 countries targeting an eventual 80-country program, and secured the first generic semaglutide approval in Canada. The company also has partnerships with Sandoz, Aspen, Innoviva Specialty Therapeutics, and others, and operates manufacturing facilities across India including biologics capacity at Bachupally and peptide API production at Vizag. Dr. Reddy's is listed on the NYSE, BSE, and NSE, and has been listed on the NYSE for 25 years. Updated
Here is a look at why companies split their stocks and why stock splits matter. Plus, upcoming stock splits to watch from Dr. Reddy's Laboratories, Southern Copper, and more.
24/7 Wall St. is looking at some big analyst calls that we have seen so far on Tuesday, including Allstate, Electronic Arts and Zillow.
Is it time to buy Amarin? The biopharmaceutical company just announced a new study showing its drug Vascepa can significantly reduce cardiovascular risk in people with diabetes.
Amarin is on hold as generic rivals seek to copy its potential blockbuster Vascepa.
Amarin is going ahead with a big marketing campaign for potential COVID treatment Vascepa after a disruption caused by the pandemic.
Amarin’s Vascepa treats cardiovascular disease, which is a big risk factor for COVID-19 patients, but is the subject of patent litigation.
Amarin will trial Vascepa as a COVID-19 treatment and that could more than offset investor concerns about patent litigation.
Amarin won FDA approval for its Vascepa cardiovascular disease drug in December but the pandemic and patent litigation are weighing on the stock.
There are still a lot of questions for Amarin must figure out before it gets back on track. For investors, the question is whether it is the market recovery that is lifting…
Amarin Corp. PLC (NASDAQ: AMRN) plans to mount a vigorous and speedy appeal of a U.S. District Court ruling that blocked its patents on the medication Vascepa, the company’s chief executive says.…
Amarin has two big problems. Getting an unfavorable court decision overruled is by far the more important.
Amarin stock was absolutely crushed at the tail end of March, and now the company is dealing with the fallout. Investors will be asking a lot of tough questions. Namely, is Amarin…
Monday's top analyst upgrades, downgrades and initiations included Alibaba, AT&T, Bank of America, BlackBerry, Boeing, Citigroup, Cloudflare, DocuSign, Lululemon Athletica, Marvell Technology, Pinterest and Verizon Communications.
India has been one of the best growth economies measured by gross domestic product for some time, but the secular growth opportunity has faced multiple setbacks in 2018 that may persist,
Everyone knows that investors will pay up to chase growth, and it is quite possible that India might be one of the best growth stories in the world for 2018 and beyond.
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company that develops, manufactures, and markets generic, biosimilar, and specialty pharmaceutical products globally.
24/7 Wall St.'s 12-month price target for RDY is $14.17, rated Buy. The Wall Street consensus target is $13.23. RDY price prediction →
